This post was originally published on this site Mirvetuximab soravtansine, an investigational antibody-drug conjugate targeting the folate receptor alpha (FRα) protein, was no better than chemotherapy at delaying disease progression or death in ovarian cancer patients included in the FORWARD I Phase 3 trial. The treatment failed to extend survival without disease worsening in the…
This post was originally published on this site An under-the-skin injection of daratumumab is as effective as its intravenous formulation, Darzalex (daratumumab), at reducing tumor burden in multiple myeloma patients, a Phase 3 clinical trial shows. The new formulation also led to similar levels of daratumumab in circulation, meeting the trial’s co-primary goals, according to Genmab, the…
This post was originally published on this site The investigational therapy ATYR1923 for pulmonary sarcoidosis may help decrease lung inflammation by halting the infiltration of immune cells called neutrophils into the lungs, according to a preclinical study in mice. Suzanne Paz, PhD, from the therapy’s developer aTyr Pharma, presented the findings in a poster, titled “ATYR1923…
This post was originally published on this site It’s a pretty well-known fact that having access to a support network is an essential tool for surviving any big life struggle. To have people to talk and relate to is extremely remedying. I’ve always known this and yet, for some reason, I never could bring myself…
This post was originally published on this site Long-term treatment with a combination of NeuVax (nelipepimut-S) and Herceptin (trastuzumab) is safe and extends the time without disease resurgence in women with triple-negative breast cancer, according to final results of a Phase 2b trial. NeuVax, developed by Sellas Life Sciences, is an investigational cancer vaccine that contains small pieces derived…
This post was originally published on this site Adding the androgen receptor inhibitor darolutamide to androgen deprivation therapy (ADT) extends by 22 months the time men with castration-resistant prostate cancer live without metastasis, without increasing the incidence of adverse events, results from a Phase 3 trial show. The treatment also extended survival, time to pain progression, time until chemotherapy…
This post was originally published on this site The U.S. Food and Drug Administration has raised concerns in its newly released briefing materials over the safety and tolerability of Karyopharm Therapeutics‘ lead compound selinexor, creating a potential stumbling block on its path to approval for heavily treated multiple myeloma. Selinexor is an oral inhibitor of the XPO1 protein that prevents tumor…
This post was originally published on this site The U.S. Food and Drug Administration has approved a new dosing regimen for the multiple myeloma treatment Darzalex (daratumumab), allowing doctors to split the first infusion over two consecutive days. The approval is based on data from the EQUULEUS Phase 1b trial (NCT01998971), where the split dosing lead to similar safety…
This post was originally published on this site Owing to an anonymous $75 million gift, New York University (NYU) Langone Health and its Laura and Isaac Perlmutter Cancer Center will establish a Center for Blood Cancers. The center is expected to house a new, state-of-the-art program for multiple myeloma, complementing its current blood malignancy programs.…
This post was originally published on this site Stephen J. Forman, MD, a physician and researcher in bone marrow transplantation and disorders such as lymphoma, is racking up some accolades. Forman will receive the 2019 DKMS Mechtild Harf Science Award on March 25 in Frankfurt, Germany, for his work in cancer research as the head of City…
